Companies in #Treatment-Resistant Depression

HMNC Brain Health is a Munich-based clinical-stage biopharmaceutical company developing personalized precision psychiatry treatments powered by AI and pharmacogenomics. Its pipeline includes two lead depression programs, one of which is an oral esketamine formulation being developed as a more convenient alternative to Johnson & Johnson's Spravato, and a separate novel mechanism in treatment-resistant depression. The company is leveraging companion-diagnostic and digital-phenotyping tools to stratify patients and improve response rates in major depressive disorder.